文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

A、D亚型HIV-1拉替拉韦治疗失败者对比克替拉韦和卡博特韦的高水平耐药

High-level resistance to bictegravir and cabotegravir in subtype A- and D-infected HIV-1 patients failing raltegravir with multiple resistance mutations.
PubMed 文献 · J Antimicrob Chemother · 2021-01-01

研究对乌干达8例拉替拉韦三线治疗失败患者的HIV-1整合酶重组病毒进行基因型和表型检测。携带单一原发突变或联合次要整合酶链转移抑制剂突变的病毒对两药仍敏感,但多重原发突变组合导致卡博特韦EC50升高429至1000倍、比克替拉韦升高60至100倍,且这些病毒整合能力降至14%至48%。

要点

  • 单一N155H或Y143R/S突变病毒对两药仍敏感
  • 多重原发突变组合(如E138A/G140A/G163R/Q148R)呈高水平交叉耐药
  • 多重耐药病毒整合能力下降至14%至48%,但耐药程度卡博特韦高于比克替拉韦

核心结论

  • 拉替拉韦经治的A、D亚型HIV-1患者中,多重整合酶原发突变组合可导致对比克替拉韦和卡博特韦高水平交叉耐药,对卡博特韦更明显。
  • 比克替拉韦和卡博特韦可作为对第一代整合酶链转移抑制剂敏感性降低的A、D亚型感染者的替代选择,但既往拉替拉韦暴露可能降低疗效。

研究设计与样本

  • 对乌干达8例拉替拉韦为基础三线治疗失败患者的HIV-1整合酶重组病毒进行基因型和表型药敏检测。
  • 在MT-4细胞中评估这些病毒的整合能力。

主要发现

  • 携带单一原发突变N155H或Y143R/S或联合次要整合酶链转移抑制剂突变(T97A、M50I、L74IM、E157Q、G163R或V151I)的病毒对两药均敏感。
  • E138A/G140A/G163R/Q148R或E138K/G140A/S147G/Q148K组合使卡博特韦EC50升高429至1000倍、比克替拉韦升高60至100倍。
  • 上述重组病毒在无药物时整合能力为14%至48%(相对WT HIV-1 NL4-3株)。

临床怎么用

  • 对既往拉替拉韦暴露且携带多重整合酶耐药突变者,使用比克替拉韦或卡博特韦前应评估耐药组合,卡博特韦耐药风险更高。

局限性

  • 样本量仅8例,来自乌干达单一队列,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The second-generation integrase strand transfer inhibitor (INSTI) bictegravir is becoming accessible in low- and middle-income countries (LMICs), and another INSTI, cabotegravir, has recently been approved as a long-acting injectable. Data on bictegravir and cabotegravir susceptibility in raltegravir-experienced HIV-1 subtype A- and D-infected patients carrying drug resistance mutations (DRMs) remain very scarce in LMICs. PATIENTS AND METHODS: HIV-1 integrase (IN)-recombinant viruses from eight patients failing raltegravir-based third-line therapy in Uganda were genotypically and phenotypically tested for susceptibility to bictegravir and cabotegravir. Ability of these viruses to integrate into human genomes was assessed in MT-4 cells. RESULTS: HIV-1 IN-recombinant viruses harbouring single primary mutations (N155H or Y143R/S) or in combination with secondary INSTI mutations (T97A, M50I, L74IM, E157Q, G163R or V151I) were susceptible to both bictegravir and cabotegravir. However, combinations of primary INSTI-resistance mutations such as E138A/G140A/G163R/Q148R or E138K/G140A/S147G/Q148K led to decreased susceptibility to both cabotegravir (fold change in EC50 values from 429 to 1000×) and bictegravir (60 to 100×), exhibiting a high degree of cross-resistance. However, these same IN-recombinant viruses showed impaired integration capacity (14% to 48%) relative to the WT HIV-1 NL4-3 strain in the absence of drug. CONCLUSIONS: Though not currently widely accessible in most LMICs, bictegravir and cabotegravir offer a valid alternative to HIV-infected individuals harbouring subtype A and D HIV-1 variants with reduced susceptibility to first-generation INSTIs but previous exposure to raltegravir may reduce efficacy, more so with cabotegravir.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Ndashimye E, Li Y, Reyes PS, et al. High-level resistance to bictegravir and cabotegravir in subtype A- and D-infected HIV-1 patients failing raltegravir with multiple resistance mutations. J Antimicrob Chemother. 2021. PMID: 34453542. doi:10.1093/jac/dkab276

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。